114 related articles for article (PubMed ID: 19961961)
1. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.
Lee HJ; Park N; Cho HJ; Yoon JK; Van ND; Oh YK; Kim YB
Vaccine; 2010 Feb; 28(6):1613-9. PubMed ID: 19961961
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.
Cho H; Lee HJ; Heo YK; Cho Y; Gwon YD; Kim MG; Park KH; Oh YK; Kim YB
PLoS One; 2014; 9(4):e95961. PubMed ID: 24759938
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.
Lee HJ; Yoon JK; Heo Y; Cho H; Cho Y; Gwon Y; Kim KC; Choi J; Lee JS; Oh YK; Kim YB
J Microbiol; 2015 Jun; 53(6):415-20. PubMed ID: 26025174
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.
Lee HJ; Hur YK; Cho YD; Kim MG; Lee HT; Oh YK; Kim YB
PLoS One; 2012; 7(11):e50296. PubMed ID: 23209698
[TBL] [Abstract][Full Text] [Related]
5. Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus.
Han SE; Kim MG; Lee S; Cho HJ; Byun Y; Kim S; Kim YB; Choi Y; Oh YK
J Appl Toxicol; 2013 Dec; 33(12):1474-83. PubMed ID: 22987290
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
7. Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.
Lee HJ; Cho H; Kim MG; Heo YK; Cho Y; Gwon YD; Park KH; Jin H; Kim J; Oh YK; Kim YB
PLoS One; 2015; 10(3):e0119408. PubMed ID: 25789464
[TBL] [Abstract][Full Text] [Related]
8. An effective DNA priming-protein boosting approach for the cervical cancer vaccination.
Kianmehr Z; Ardestani SK; Soleimanjahi H; Farahmand B; Abdoli A; Khatami M; Akbari K; Fotouhi F
Pathog Dis; 2015 Mar; 73(2):1-8. PubMed ID: 25722486
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.
Yoon SW; Lee TY; Kim SJ; Lee IH; Sung MH; Park JS; Poo H
Vaccine; 2012 May; 30(22):3286-94. PubMed ID: 22426329
[TBL] [Abstract][Full Text] [Related]
10. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
11. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
12. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.
Choi JY; Gwon YD; Kim JK; Cho YD; Heo YK; Cho HS; Choi TJ; Poo HR; Oh YK; Kim YB
PLoS One; 2013; 8(11):e80762. PubMed ID: 24260476
[TBL] [Abstract][Full Text] [Related]
14. A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.
Chen X; Liu H; Zhang T; Liu Y; Xie X; Wang Z; Xu X
PLoS One; 2014; 9(5):e95448. PubMed ID: 24802101
[TBL] [Abstract][Full Text] [Related]
15. Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.
Hongli L; Xukui L; Ting L; Wensheng L; Lusheng S; Jin Z
Hum Vaccin Immunother; 2013 Jan; 9(1):83-9. PubMed ID: 23108357
[TBL] [Abstract][Full Text] [Related]
16. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
17. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.
Cho HJ; Kim JY; Lee Y; Kim JM; Kim YB; Chun T; Oh YK
Vaccine; 2010 Mar; 28(14):2598-606. PubMed ID: 20116467
[TBL] [Abstract][Full Text] [Related]
18. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
Yan X; Wang D; Liang F; Fu L; Guo C
Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
[TBL] [Abstract][Full Text] [Related]
19. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
20. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]